Compared with white Canadians, Aboriginal Canadians have a higher prevalence of end-stage renal disease,\(^1\) which is generally attributed to their increased risk for diabetes. However, there has been limited investigation of the incidence and causes of end-stage renal disease among Aboriginal children and young adults. Because most incident cases of diabetes are identified in middle-aged adults, an excess risk of end-stage renal disease in young people would not be expected if the high risk of diabetes is responsible for higher overall rates of end-stage renal disease among Aboriginal people. About 12.3% of children with end-stage renal disease in Canada are Aboriginal,\(^1\) but only 6.1% of Canadian children (age < 19 yr) are Aboriginal.\(^4\)

A few reports suggest that nondiabetic renal disease is common among Aboriginal populations in North America.\(^2\) Aboriginal adults in Saskatchewan are twice as likely as white adults to have end-stage renal disease caused by glomerulonephritis,\(^3\) and an increased rate of mesangial proliferative glomerulonephritis has been reported among Aboriginal people in the United States.\(^4\) These studies suggest that diabetes may be a comorbid condition rather than the sole cause of kidney failure among some Aboriginal people in whom diabetic nephropathy is diagnosed using clinical features alone.

We estimated incidence rates of end-stage renal disease among Aboriginal children and young adults in Canada and compared them with the rates seen among white children and young adults. In addition, we compared relative odds of congenital renal disease, glomerulonephritis and diabetic nephropathy in Aboriginal people with the relative odds of these conditions in white people.
Methods

Data source
We obtained data from the Canadian Organ Replacement Register, which contains data for all patients with incident end-stage renal disease in Canada. In a recent validation study comparing registry data with detailed clinical data from patient-level medical records, agreement between the two for primary renal disease was reported as 82.8% for glomerulonephritis and 78.3% for diabetes. Lower agreement was noted for ethnicity (58%); however, discrepancies were frequently due to a specific race reported in the register, but reported as unknown in medical records. The Conjoint Health Research Ethics Board of the University of Calgary approved the study.

Study population
Our study involved an incident cohort of all patients less than 22 years of age included in the register during the period Jan. 1, 1992, to Dec. 31, 2007. We calculated age- and sex-specific incidence rates of end-stage renal disease. In addition, we randomly selected a cohort of adult patients with end-stage renal disease (age ≥ 18 yr), comprising 75% of adult registrants during the period from Jan. 1, 1990, to Dec. 31, 2000, to calculate odds of glomerulonephritis, diabetes and congenital renal disease by age category in Aboriginal and white patients. The adult dataset comprised two 37.5% random cohorts that had been previously obtained by one of the investigators (Marcello Tonelli). From this dataset, we excluded patients between the ages of 18 and less than 22 years, because all patients less than 22 years of age were captured in the incident cohort. Therefore, we did not have data on all adult patients with incident end-stage renal disease, and we did not calculate incidence rates for adults 22 years of age and older. Furthermore, we did not include patients from the province of Quebec, because their data were not available for release to investigators at the time of the study. Finally, we excluded recipients of organ transplants other than kidney.

Ethnicity was determined by the health care professional responsible for reporting to the register and was classified as white or Aboriginal (First Nations, Inuit and Métis, including Aboriginal people living on federal reserves). We excluded patients whose ethnicity was not white or Aboriginal.

Statistical analysis
We described baseline clinical characteristics with either medians and interquartile ranges (IQRs) or proportions. We used a significance level of α = 0.05 for all statistical tests. We compared characteristics of Aboriginal and white people using $\chi^2$ tests for categorical variables.

We calculated age- and sex-specific incidence rates (age categories 0 to < 5 yr, 5 to < 10 yr, 10 to < 15 yr, 15 to < 18 yr, 18 to < 22 yr) of end-stage renal disease, with 95% confidence intervals (CIs), for Aboriginal people for the duration of the study period. We calculated incidence rate ratios (IRRs) between Aboriginal and white people using unconditional maximum likelihood estimation. We obtained population numbers by age, sex, province and ethnicity from Statistics Canada for census years 1996, 2001 and 2006 to match registrant data, excluding the population of Quebec.

We grouped primary renal disease into 4 categories: congenital anomalies of the kidneys or urinary tract, glomerulonephritis, diabetes and other. We calculated odds ratios (ORs) for each of three causes of end-stage renal disease (congenital anomalies, diabetes, glomerulonephritis) for Aboriginal people compared with white people of the same age (age categories 0 to < 22 yr, 22 to < 40 yr, 40 to < 60 yr, ≥ 60 yr). We did not calculate ORs for the group identified as “other” primary renal diseases owing to the heterogeneity of diseases in this group.

Among patients with glomerulonephritis, we modelled the odds of having primary versus secondary glomerulonephritis for Aboriginal people compared with white people, adjusting for age and including an interaction term between age and ethnicity. Primary glomerulonephritis usually involves the kidney only (e.g., immunoglobulin A [IgA] nephropathy and membranoproliferative glomerulonephritis); in secondary glomerulonephritis, kidney involvement is part of a systemic disorder. We calculated proportions for common clinical presentations of glomerulonephritis for Aboriginal people compared with white people of the same age. We also calculated ORs for the most common subtypes of glomerulonephritis (IgA nephropathy and systemic lupus erythematosus) for Aboriginal people compared with white people of the same age. We pooled analyses across sex for all calculations owing to small samples in some categories.

A full list of renal diseases and the classification criteria we used is provided in Appendix 1 (available at www.cmaj.ca/lookup/suppl/doi:10.1503/cmaj.120427/-/DC1).

Results

Study population
A total of 159 Aboriginal and 821 white children and young adults (age < 22 yr) started renal replacement therapy during the study period.
The age of patients at the start of therapy did not differ significantly between Aboriginal and white patients (Table 1). Compared with white patients, a greater proportion of Aboriginal patients with incident end-stage renal disease were girls or young women (61.0% v. 46.4%, \( p = 0.001 \)) (Table 1).

There were 1113 Aboriginal and 19 363 white patients in a random sample of 75% of adult patients with end-stage renal disease who started renal replacement therapy between 1990 and 2000. Compared with white patients, a greater proportion of Aboriginal patients were women (53.1% v. 39.1%; \( p < 0.001 \)).

### Incidence of end-stage renal disease

Incidence rates of end-stage renal disease generally increased with age (Table 2). The rate was highest among Aboriginal women aged 18 to less than 22 years (68.25 per million age-related population). When all age categories were combined, IRRs for Aboriginal people were significantly greater for boys (1.82, 95% CI 1.40–2.38) and girls (3.24, 95% CI 2.60–4.05) (Table 2).

### Causes of end-stage renal disease

Among patients younger than 22 years, a smaller proportion of Aboriginal patients than white patients had end-stage renal disease caused by congenital anomalies (17.0% v. 26.9%; OR 0.56, 95% CI 0.36–0.86) (Figure 1 and Table 3).

Compared with white patients in the same age group, a greater proportion of Aboriginal people younger than 22 years had end-stage renal disease caused by glomerulonephritis (50.9% v. 32.3%; OR 2.18, 95% CI 1.55–3.07) (Figure 1 and Table 3). Glomerulonephritis was

---

### Table 1: Demographic characteristics of patients with incident end-stage renal disease by ethnicity

| Characteristic                      | Aboriginal | White | \( p \) value* |
|-------------------------------------|------------|-------|---------------|
| **Children and young adults (Incident)** |            |       |               |
| No. of patients (%)                 | n = 159    | n = 821 |               |
| Female sex                          | 97 (61.0)  | 381 (46.4) | 0.001         |
| Age at start of renal replacement therapy, yr |           |       |               |
| 0 to < 5                            | 16 (10.1)  | 88 (10.7)   | 0.94          |
| 5 to < 10                           | 16 (10.1)  | 91 (11.1)    |               |
| 10 to < 15                          | 37 (23.3)  | 179 (21.8)   |               |
| 15 to < 18                          | 35 (22.0)  | 163 (19.9)   |               |
| 18 to < 22                          | 55 (34.6)  | 300 (36.5)   |               |
| **Adults (75% sample)**             | n = 1 113  | n = 19 363 |               |
| Female sex                          | 591 (53.1) | 7 570 (39.1) | < 0.001       |
| Age at start of renal replacement therapy, yr |           |       |               |
| 22 to < 40                          | 168 (15.1) | 2 381 (12.3) | < 0.001       |
| 40 to < 60                          | 545 (49.0) | 5 434 (28.1) |               |
| \( \geq 60 \)                       | 400 (35.9) | 11 548 (59.6) | < 0.001      |
| Comorbidity                         |            |       |               |
| Type 1 diabetes†                    | 296 (26.6) | 3 140 (16.2) | < 0.001       |
| Type 2 diabetes†                    | 462 (41.5) | 3 510 (18.1) | < 0.001       |
| Myocardial Infarction               | 162 (14.6) | 3 889 (20.0) | < 0.001       |
| Pulmonary edema                     | 355 (31.9) | 5 528 (28.5) | 0.02          |
| Stroke or TIA                       | 105 (9.4)  | 2 042 (10.5) | 0.24          |
| Chronic lung disease                | 85 (7.6)   | 2 131 (11.0) | < 0.001       |
| Peripheral vascular disease         | 224 (20.1) | 3 595 (18.6) | 0.19          |
| Malignancy                          | 45 (4.0)   | 1 854 (9.6)  | < 0.001       |

Note: TIA = transient ischemic attack.
*\( \chi^2 \) test.
†Includes diabetes as a cause of end-stage renal disease and/or as a comorbidity.

### Table 2: Age- and sex-specific incidence rates and incidence rate ratios of end-stage renal disease among Aboriginal and white children and adolescents

| Age group, yr | Incidence rate* | IRR (95% CI)† |
|---------------|-----------------|---------------|
| Aboriginal    | White           |               |
| 0 to < 5      | 11.86           | 1.99 (0.98–4.05) |
| 5 to < 10     | 7.65            | 1.63 (0.69–3.82) |
| 10 to < 15    | 13.12           | 1.59 (0.83–3.07) |
| 15 to < 18    | 32.95           | 2.09 (1.19–3.66) |
| 18 to < 22    | 49.05           | 2.23 (1.44–3.45) |
| Overall       | 19.38           | 1.82 (1.40–2.38) |

| Aboriginal    | White           |               |
| 0 to < 5      | 9.62            | 2.02 (0.90–4.53) |
| 5 to < 10     | 12.20           | 5.30          |
| 10 to < 15    | 36.97           | 3.60 (2.35–5.52) |
| 15 to < 18    | 51.50           | 4.36 (2.67–7.12) |
| 18 to < 22    | 68.25           | 3.77 (2.56–5.55) |
| Overall       | 31.45           | 3.24 (2.60–4.05) |

Note: CI = confidence interval, IRR = incidence rate ratio.
*Rates are calculated as cases per million age-related population using data from the Canadian census in 1996, 2001 and 2006.
†IRR = 1.00 indicates equal incidence in both groups; IRR >1 indicates higher incidence among Aboriginal children and young adults than among white children and young adults.
also a more common cause of end-stage renal disease among Aboriginal people aged 22 to less than 40 years (42.9%) than among white people (34.6%) in the same age group (OR 1.42; 95% CI 1.03–1.95) (Figure 1 and Table 3). In contrast, fewer Aboriginal patients aged 40 years and older had end-stage renal disease caused by glomerulonephritis (14.1% for patients aged 40 to < 60 yr, 7.8% for patients aged ≥ 60 yr) compared with white people in the same age groups (24.6% for patients aged 40 to < 60 yr, 15.4% for patients aged ≥ 60 yr) (Figure 1 and Table 3).

Among patients of all ages with end-stage renal disease caused by diabetes (n = 6035), 58.9% of Aboriginal people had type 2 diabetes, whereas a much smaller proportion of white people (43.7%) had type 2 diabetes as the cause (p < 0.001). The OR for diabetes as the cause of end-stage renal disease was not calculated separately for patients less than 22 years of age, because the sample size was too small to yield an accurate estimate (3 Aboriginal patients, 2 white patients) (Table 3). We saw no significant difference in the proportion of Aboriginal versus white people aged 22 to less than 40 years with end-stage renal disease caused by diabetes. Among patients in this group (n = 804), 40.0% of Aboriginal people had end-stage renal disease caused by type 2 diabetes, whereas 3.4% of white people had type 2 diabetes as the cause (p < 0.001) (data not shown). Among patients 40 years of age and older, diabetes was a more common cause of end-stage renal disease among Aboriginal people (70.5% for patients aged 40 to < 60 yr and 65.8% for patients aged ≥ 60 yr) than among white people (33.9% for patients aged 40 to < 60 yr and 23.7% for patients aged ≥ 60 yr) (Figure 1).

Among patients who had glomerulonephritis (n = 4465), 78.9% of Aboriginal people and 82.9% of white people had primary glomerulonephritis (data not shown). There was no difference in odds of primary versus secondary glomerulonephritis in Aboriginal people compared with white people when we adjusted for age (OR 1.10, 95% CI 0.79–1.50) (data not shown).

Among patients younger than 22 years with glomerulonephritis as a cause of end-stage renal disease, IgA and mesangial proliferative nephropathies (28.8% v. 17.6%; OR 3.05, 95% CI 1.72–5.41) were more common among Aboriginal people than among white people. However, we saw no significant difference in the proportion of Aboriginal people versus white people in this age group with systemic lupus erythematosus (11.3% v. 7.6%; OR 2.29, 95% CI 1.03–5.09) (Figure 2 and data not shown).

**Interpretation**

Using data from a national registry, we found a significantly higher risk of end-stage renal disease among Aboriginal children and young adults than among their white counterparts. The high risk of this condition in Aboriginal adults is usually attributed to a higher prevalence of diabetes and, thus, diabetic nephropathy. However, diabetes is an unlikely cause of end-stage renal disease in children and young adults. Our results suggest that the higher incidence of end-stage renal disease among young Aboriginal people is due to their higher risk of glomerulonephritis compared with young white people. Furthermore, congenital anomalies (a major cause of kidney failure in chil-

---

**Table 3:** Odds of congenital anomalies of the kidney and urinary tract, glomerulonephritis and diabetes as the cause of end-stage renal disease in Aboriginal people compared with white people

| Age group, yr | Congenital renal disease | Glomerulonephritis | Diabetes |
|--------------|--------------------------|--------------------|----------|
| 0 to < 22    | 0.56 (0.36–0.86)         | 2.18 (1.55–3.07)   | —†       |
| 22 to < 40   | 0.57 (0.26–1.24)         | 1.42 (1.03–1.95)   | 0.91 (0.65–1.29) |
| 40 to < 60   | 0.27 (0.08–0.85)         | 0.51 (0.39–0.65)   | 4.66 (3.84–5.65) |
| ≥ 60         | 0.53 (0.13–2.16)         | 0.46 (0.32–0.67)   | 6.17 (5.00–7.62) |

Note: CI = confidence interval, OR = odds ratio.
*OR > 1.00 indicates higher odds of disease in Aboriginal people, OR < 1.00 indicates higher odds of disease in white people.
†The sample size was too small to permit an accurate estimate.
dren) were less common in Aboriginal people than in white people of all ages.

Ours is not the first study to suggest that glomerulonephritis is a more common cause of end-stage renal disease in Aboriginal people than in white people. A study involving 247 children in Manitoba found that Aboriginal children were 6 times more likely than white children to present with acquired renal disease (including IgA nephropathy and nephrotic syndrome). In a cohort of Aboriginal children who received renal transplants in British Columbia ($n = 24$), 58.3% had glomerulonephritis and 12.5% had congenital anomalies causing end-stage renal disease. This observation is striking, because congenital anomalies generally account for 30%–60% of pediatric end-stage renal disease in North American and European cohorts.

Most previous studies that found higher proportions of Aboriginal children with glomerulonephritis, compared with white children, were single-centre studies and therefore had limited generalizability. Our study used a national sample, thereby improving the generalizability of our results and providing more precise estimates of incidence and odds of the causes of disease. Our large sample allowed us to examine primary and secondary glomerulonephritis separately. Sim-

![Figure 2: Percentage of patients with various clinical presentations of glomerulonephritis, by age and ethnicity. ANCA = antineutrophil cytoplasmic antibody.](image-url)
ilar to previous observations, we also found a significantly higher proportion of Aboriginal people with both IgA nephropathy and systemic lupus erythematosus compared with white people.

The increased risk of end-stage renal disease (particularly due to glomerulonephritis) that we saw among Aboriginal people raises the question “Why is this happening?” The risk of glomerulonephritis in a given population is determined by complex interactions between genetic predisposition, environmental exposures, socioeconomic conditions and infections. We were unable to determine adjusted risk estimates for infection-related glomerulonephritis for Aboriginal children. The same socioeconomic and health disparities that lead to poor health outcomes among Aboriginal adults might also cause increased risk of progression to end-stage renal disease in Aboriginal children and young adults.

Among patients aged 40 years and older, we saw a lower risk of glomerulonephritis in Aboriginal people than in white people. However, it is possible that the increased risk of glomerulonephritis seen in young Aboriginal people extends to Aboriginal people in this older age group. The frequency of kidney biopsy among adults with diabetes and end-stage renal disease can be less than 20%, raising the possibility that diabetes is a comorbid condition rather than the sole cause of kidney failure among some Aboriginal adults with a diagnosis of diabetic nephropathy. Either a high frequency of glomerulonephritis in people with diabetes or coexistence of glomerulonephritis with diabetic glomerulosclerosis has been reported among various cohorts of non-Aboriginal patients.

In an observational study involving 567 consecutive renal biopsies in European patients with type 1 or 2 diabetes and chronic kidney disease, about 70% of patients had diabetic nephropathy and 30% had other glomerular diseases (e.g., immune complex glomerulonephritis, secondary focal glomerulosclerosis, IgA nephropathy). In an Australian cohort of patients with diabetes, concomitant nondiabetic renal disease (mostly glomerulonephritis and tubulointerstitial disease) with diabetic glomerulosclerosis was found in 38 of 136 (28%) consecutive renal biopsies done primarily for proteinuria.

A study involving 90 children (98% First Nations or Métis) with type 2 diabetes from Manitoba also supports the possibility that diabetes is a comorbid condition. In that study, 16% of participants had persistent macroalbuminuria within 8 years of receiving their diagnosis. Of the 10 renal biopsies that were done, 9 showed immune complex disease or glomerulosclerosis; none of them showed classic diabetic nephropathy. Thus, the potential for misdiagnosis and missed curative treatment of coexistent renal disease is particularly important given the high frequency of diabetes and low frequency of glomerulonephritis we saw among Aboriginal adults 40 years of age and older.

Furthermore, we suggest that more liberal use of kidney biopsy for definitive diagnosis may be justified in the Aboriginal population.

**Limitations**

We relied on voluntary reporting of incident patients to the Canadian Organ Replacement Register. Ethnicity is reported at the discretion of the health care professional reporting to the register; as a result, misclassification may occur and cannot be verified.

Aboriginal ethnicity in the Canadian Organ Replacement Register includes people who self-identify as First Nations, Inuit or Métis, which are inherently distinct and diverse populations. For this reason, there may be important genetic differences between these groups.

We had no independent verification of primary renal disease or access to biopsy reports. Furthermore, our analysis is limited to patients who have reached end-stage renal disease, and we do not have biopsy results or information about the larger group of people with chronic kidney disease in the population.

**Conclusion**

Aboriginal children and young adults are at increased risk of end-stage renal disease compared with white children and young adults. This increased risk is apparently driven by an increased risk of glomerulonephritis that is present at least until the age of 40 years. Further studies are warranted to determine the reasons for the higher risk of glomerulonephritis among young Aboriginal people, and whether an excess risk of biopsy-proven glomerulonephritis is also present in Aboriginal adults aged 40 years and older. More liberal use of kidney biopsy should be considered for Aboriginal people with diabetes and proteinuria.

**References**

1. Hemmelgarn BR. CSCI Joe Doupe lecture: end-stage renal disease among Aboriginal people. Clin Invest Med 2006;29:383-7.
2. Dyck RF. Mechanisms of renal disease in indigenous populations: influences at work in Canadian indigenous peoples. Nephrology (Carlton) 2001;6:3-7.
3. Samuel SM, Foster BJ, Tonelli MA, et al. Dialysis and transplantation among Aboriginal children with kidney failure. CMAJ 2011;183:E665-72.
4. Canada (Code01) (table). Aboriginal population profile. 2006 Census. Ottawa (ON): Statistics Canada; 2007. Cat. no. 92-594-XWE. Available: www12.statcan.ca/census-recensement/2006/dp-pd/fprod092-594/index.cfm?Lang=E (accessed 2012 July 4).
5. Canada (Code01) (table). 2006 community profiles. 2006 Census. Ottawa (ON): Statistics Canada; 2007. Cat. no. 92-591-XWE. Available: www12.statcan.ca/census-recensement/2006/dp-pd/fprod092-591/index.cfm?Lang=E (accessed 2012 July 4).
6. Hoy WE, Smith SM, Hughson MD, et al. Mesangial proliferative glomerulonephritis in southwestern American Indians. Transplant Proc 1989;21:3909-12.
32. Robinson LA, Howell DN, Wigfall DR, et al. Appearance of

30. Haider DG, Peric S, Friedl A, et al. Kidney biopsy in patients

26. McDonald SP, Russ GR. Current incidence, treatment patterns

27. Narva A, Stiles S, Karp S, et al. Access of Native Americans to

23. Bramley D, Hebert P, Jackson R, et al. Indigenous disparities in

13. Sellers EA, Blydt-Hansen TD, Dean HJ, et al. Macroalbumin-

20. McGrogan A, Franssen CF, de Vries CS. The incidence of pri-

19. Smith SM, Tung KS. Incidence of IgA-related nephritides in

14. van Stralen KJ, Tizard EJ, Verrina E, et al. Demographics of paedi-

11. Newman JM, Marfin AA, Eggers PW, et al. End-stage renal dis-

17. Matsuda-Abedini M, Al-Alsheikh K, Hurley RM, et al. Outcome

16. Bulloch B, Postl BD, Ogborn MR. Excess prevalence of non

15. Samuel SM, Tonelli MA, Foster BJ, et al. Survival in pediatric dial-

12. Megill DM, Hoy WE, Woodruff SD. Rates and causes of end-stage

7. Dyck RF, Tan L. Rates and outcomes of diabetic end-stage renal
disease among registered native people in Saskatchewan. CMAJ.
1994;150:203-8.

8. Dyck RF, Tan L. Non-diabetic end-stage renal disease among
Saskatchewan Aboriginal people. Clin Invest Med 1998;21:33-8.

9. Hughson MD, Megill DM, Smith SM, et al. Mesangiocapillary
glomerulonephritis in Zuni (New Mexico) Indians. Arch Pathol
Lab Med 1989;113:148-57.

10. Moos LM, Richards HA, Miskulin D, et al. A validation study of
the Canadian Organ Replacement Register. Clin J Am Soc Nephrol
2011;6:813-8.

11. Newman JM, Marfin AA, Eggers PW, et al. End-state renal dis-
ea among Native Americans, 1983-86. Am J Public Health
1990;80:318-9.

12. Megill DM, Hoy WE, Woodruff SD. Rates and causes of end-stage
renal disease in Navajo Indians, 1971-1985. West J Med 1988;149:
178-82.

13. Sellers EA, Blydt-Hansen TD, Dean HJ, et al. Macroalbumin-
uria and renal pathology in First Nation youth with type 2 dia-
betes. Diabetes Care 2009;32:786-90.

14. van Stralen KJ, Tizard EJ, Verrina E, et al. Demographics of paediat-
cric renal replacement therapy in Europe. 2007 annual report of
the ESPN/ERA-EDTA registry. Pediatr Nephrol 2010;25:1379-82.

15. Samuel SM, Tonelli MA, Foster BJ, et al. Survival in pediatric dial-
ysis and transplant patients. Clin J Am Soc Nephrol 2011;6:1094-9.

16. Bulloch B, Postl BD, Ogborn MR. Excess prevalence of non
diabetic renal disease in native American children in Manitoba.
Pediatr Nephrol 1996;10:702-4.

17. Matsuda-Abedini M, Al-Alsheikh K, Hurley RM, et al. Outcome
of kidney transplantation in Canadian Aboriginal children in the
province of British Columbia. Pediatr Transplant 2009;13:856-60.

18. van der Heijden BJ, van Dijk PJ, Verrier-Jones K, et al. Renal
replacement therapy in children: data from 12 registries in Europe.
Pediatr Nephrol 2004;19:213-21.

19. Smith SM, Tang KS. Incidence of IgA-related nephritides in
American Indians in New Mexico. Hum Pathol 1985;16:181-4.

20. McGrogan A, Franssen CF, de Vries CS. The incidence of pri-
mary glomerulonephritis worldwide: a systematic review of the
literature. Pediatr Nephrol Transplant 2011;26:414-30.

21. Johnson RJ, Hurtado A, Merszei J, et al. Hypothesis: dysregula-
tion of immunologic balance resulting from hygiene and socio-
economic factors may influence the epidemiology and cause of
glomerulonephritis worldwide. Am J Kidney Dis 2005;42:575-81.

22. Barsoum RS. Glomerulonephritis in disadvantaged populations.
Clin Nephrol 2010;74(Suppl 1):44-50.

23. Bramley D, Hebert P, Jackson R, et al. Indigenous disparities in
disease-specific mortality, a cross-country comparison: New
Zealand, Australia, Canada, and the United States. N Engl J Med
2004;317:1215.

24. Cass A, Cunningham J, Snellng P, et al. Renal transplantation
for indigenous Australians: identifying the barriers to equitable
access. Ethn Health 2003;8:111-9.

25. Gao S, Manns BJ, Cullerton BF, et al. Prevalence of chronic kid-
ney disease and survival among aboriginal people. J Am Soc
Nephrol 2007;18:2953-9.

26. McDonald SP, Russ GR. Current incidence, treatment patterns
and outcome of end-stage renal disease among indigenous groups
in Australia and New Zealand. Nephrology (Carlton) 2003;8:42-8.

27. Narva A, Siiles S, Karp S, et al. Access of Native Americans to
renal transplantation in Arizona and New Mexico. Blood Purif
1996;14:293-304.

28. Yeates KE, Cass A, Sequist TD, et al. Indigenous people in Aus-
tralia, Canada, New Zealand and the United States are less likely
to receive renal transplantation. Kidney Int 2009;76:59-64.

29. Taft JL, Billson VR, Nankervis A, et al. A clinical-biostatistical
study of individuals with diabetes mellitus and proteinuria. Dia-
bet Med 1990;7:215-21.

30. Haider DG, Pers C, Friedl A, et al. Kidney biopsy in patients
with diabetes mellitus. Clin Nephrol 2011;76:180-5.

31. Soni SS, Govrishankar S, Kishan AG, et al. Non-diabetic renal
disease in type 2 diabetes mellitus. Nephrology (Carlton) 2006;
11:533-7.

32. Robinson LA, Howell DN, Wigfall DR, et al. Appearance of
immune complex glomerulonephritis following the onset of type
I diabetes mellitus in a child. Am J Kidney Dis 1997;30:713-6.

Affiliations: From the Division of Pediatric Nephrology, Department of Pediatrics (Samuel), the Division of Nephrology, Department of Medicine (Hemmelgarn), the Department of Family Medicine (Crowshoe) and the Department of Community Health Sciences (Soo, Nettel-Aguirre, Hemmelgarn), University of Calgary, Calgary, Alta.; Alberta Children’s Hospital (Samuel, Nettel-Aguirre), and the Alberta Children’s Hospital Research Institute for Child and Maternal Health (Samuel, Nettel-Aguirre), Calgary, Alta.; the Division of Pediatric Nephrology, Department of Pediatrics and Department of Epidemiology, Biostatistics, and Occupational Health (Foster), McGill University, Montréal, Que.; Montreal Children’s Hospital (Foster), Montréal, Que.; the Division of Pediatric Nephrology, Department of Pediatrics (Alexander), and the Division of Nephrology, Department of Medicine (Tonelli), University of Alberta, Edmonton, Alta.; Stollery Children’s Hospital (Alexander), Edmonton, Alta.

Contributors: Susan Samuel, Bethany Foster and Marcello Tonelli conceived the idea for the study. Susan Samuel, Brenda Hemmelgarn and Marcello Tonelli obtained the data, Andrea Soo and Alberto Nettel-Aguirre designed the analysis, and Andrea Soo conducted the analysis. Susan Samuel and Marcello Tonelli wrote the manuscript. All of the authors critically reviewed the results and revised the manuscript for important intellectual content. All of the authors approved the final version submitted for publication.

Funding: This work was funded by operating grants from the Alberta Children’s Hospital Foundation. Dr. Samuel was supported by an Alberta Heritage Foundation for Medical Research Clinical Fellowship Award during the data collection period of this study, and she is currently funded by a joint Canadian Institutes of Health Research (CIHR) Canadian Child Health Clinician Scientist Career Development Award and KRESNEW Investigator award (Kidney Foundation of Canada). Dr. Foster holds a Fonds de la recherche en santé du Québec Chercheur–Boursier Clinicien award. Dr. Tonelli is supported by a Government of Canada Research Chair in the Optimal Care of People with Chronic Kidney Disease and by a Population Health Scholar award from Alberta Heritage Foundation for Medical Research. Dr. Hemmelgarn is supported by a Population Health Investigator Award from Alberta Heritage Foundation for Medical Research and by the Roy and Vi Baay Chair in Kidney Research at the University of Calgary. Dr. Alexander is supported by a Clinician Scientist Award from the Canadian Institutes for Health Research, a KRESNEW Investigator Award and an Alberta Heritage Foundation for Medical Research Clinical Investigator Award. The funding agencies did not participate in analyses or influence the decision to submit the manuscript for publication.

Acknowledgements: The authors thank the director and per-
sonnal of the Canadian Organ Replacement Register at the Canadian Institute for Health Information for their assistance in providing the data used in this study. This work was pre-
sented in poster form at the World Congress of Nephrology (WCN) 2011 meeting in Vancouver, BC, and as an oral pre-
sentation at the WCN satellite meeting for kidney disease in disadvantages populations in Victoria, BC.

Disclaimer: Parts of this material are based on data and information provided by the Canadian Institute for Health Information. However, the analyses, conclusions, opinions and statements expressed herein are those of the authors and not those of the Canadian Institute for Health Information.